Literature DB >> 11244313

Effects of allopurinol on renal stone formation and osteopontin expression in a rat urolithiasis model.

T Yasui1, M Sato, K Fujita, Y Ito, S Nomura, K Kohri.   

Abstract

BACKGROUND: The inhibitory effect of allopurinol on calcium oxalate urolithiasis has been reported, but its effect on stone matrix proteins has not been studied in vivo. To clarify the effect of allopurinol on the matrix, we investigated its effect on the expression of osteopontin (OPN), which we previously identified as an important stone matrix protein.
METHODS: Control rats were not treated. Rats of the stone group were given ethylene glycol (EG) and vitamin D(3), while the allopurinol groups (low-dose group and high-dose group) were treated with allopurinol in addition to receiving EG and vitamin D(3).
RESULTS: The rate of renal stone formation was lower in the allopurinol groups than in the stone group. This was associated with a low expression of OPN mRNA in allopurinol-treated rats relative to that in the stone group.
CONCLUSION: Allopurinol was effective in preventing calcium oxalate stone formation and reduced OPN expression in rats. Our results suggest that allopurinol prevents renal stone formation by acting against not only the control of oxalate but also OPN expression. Copyright 2001 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11244313     DOI: 10.1159/000045907

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  2 in total

1.  Successful formation of calcium oxalate crystal deposition in mouse kidney by intraabdominal glyoxylate injection.

Authors:  Atsushi Okada; Shintaro Nomura; Yuji Higashibata; Masahito Hirose; Bing Gao; Mugi Yoshimura; Yasunori Itoh; Takahiro Yasui; Keiichi Tozawa; Kenjiro Kohri
Journal:  Urol Res       Date:  2007-02-14

Review 2.  Kidney stones in anorexia nervosa: a case report and review of the literature.

Authors:  L M Jonat; C L Birmingham
Journal:  Eat Weight Disord       Date:  2003-12       Impact factor: 4.652

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.